Advertisement

International Orthopaedics

, Volume 43, Issue 7, pp 1741–1747 | Cite as

Survival analysis of elderly patients with osteosarcoma

  • Yoshinori ImuraEmail author
  • Satoshi Takenaka
  • Shigeki Kakunaga
  • Takaaki Nakai
  • Toru Wakamatsu
  • Hidetatsu Outani
  • Takaaki Tanaka
  • Hironari Tamiya
  • Kazuya Oshima
  • Kenichiro Hamada
  • Norifumi Naka
  • Nobuhito Araki
  • Ikuo Kudawara
  • Takafumi Ueda
  • Hideki Yoshikawa
Original Paper
  • 53 Downloads

Abstract

Background

Few studies have described the characteristics and prognostic factors of elderly patients with osteosarcoma. We retrospectively investigated clinico-pathological features and prognostic factors in osteosarcoma patients > 40 years old.

Methods

Patients with high-grade osteosarcoma > 40 years old who were treated at our institutions from 2000 to 2016 were recruited for this study. Information on patient, tumour, and treatment-related factors was collected and statistically analyzed. The median follow-up was 26.5 months (range, 5–139 months) for all patients.

Results

Fifty patients (30 males and 20 females) were included. The median age at diagnosis was 59.5 years (range, 41–81 years). The primary lesions were found in the limbs in 32 patients, trunk in 12, and craniofacial bones in six. Primary and secondary osteosarcoma occurred in 41 and 9 patients, respectively. Eight patients exhibited initial distant metastasis. Definitive surgery and chemotherapy were performed in 39 patients each. The rate of good responders after neoadjuvant chemotherapy was 38%. The five year overall survival (OS) rates for all patients and those without distant metastasis at diagnosis were 44.5% and 51.1%, respectively. Multivariate analysis showed that definitive surgery was the only significant prognostic factor in non-metastatic patients. The five year OS and disease-free survival (DFS) rates for non-metastatic patients who received definitive surgery were 64.3% and 60%, respectively. Among these patients, neoadjuvant and/or adjuvant chemotherapy significantly improved both OS and DFS.

Conclusions

Complete surgical resection and intensive chemotherapy should be performed for osteosarcoma patients > 40 years old despite distinct clinicopathological characteristics from those of younger patients.

Keywords

Osteosarcoma Elderly patients Distant metastasis Definitive surgery Neoadjuvant and/or adjuvant chemotherapy 

Notes

Acknowledgments

This work was supported by JSPS KAKENHI Grant Number JP16H05448 and Grant of Japan Orthopaedics and Traumatology Research Foundation, Inc.372. We thank Enago for providing high-quality editing service.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543CrossRefGoogle Scholar
  2. 2.
    Bacci G, Picci P, Ferrari S et al (1993) Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72:3227–3238CrossRefGoogle Scholar
  3. 3.
    Bacci G, Longhi A, Fagioli F et al (2005) Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 41:2836–2845CrossRefGoogle Scholar
  4. 4.
    Ferrari S, Smeland S, Mercuri M et al (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852CrossRefGoogle Scholar
  5. 5.
    Carsi B, Rock MG (2002) Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 397:53–61Google Scholar
  6. 6.
    Grimer RJ, Cannon SR, Taminiau AM et al (2003) Osteosarcoma over the age of forty. Eur J Cancer 39:157–163CrossRefGoogle Scholar
  7. 7.
    Okada K, Hasegawa T, Nishida J et al (2004) Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases—an experience in northern Japan. Ann Surg Oncol 11:998–1004CrossRefGoogle Scholar
  8. 8.
    Manoso MW, Healey JH, Boland PJ et al (2005) De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. Clin Orthop Relat Res 438:110–115CrossRefGoogle Scholar
  9. 9.
    Jeon DG, Lee SY, Cho WH et al (2006) Primary osteosarcoma in patients older than 40 years of age. J Korean MedSci 21:715–718CrossRefGoogle Scholar
  10. 10.
    Longhi A, Errani C, Gonzales-Arabio D et al (2008) Osteosarcoma in patients older than 65 years. J Clin Oncol 26:5368–5373CrossRefGoogle Scholar
  11. 11.
    Nishida Y, Isu K, Ueda T et al (2009) Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J Surg Oncol 100:48–54CrossRefGoogle Scholar
  12. 12.
    Iwata S, Ishii T, Kawai A et al (2014) Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol 21:263–268CrossRefGoogle Scholar
  13. 13.
    Joo MW, Shin SH, Kang YK et al (2015) Osteosarcoma in Asian populations over the age of 40 years: a multicenter study. Ann Surg Oncol 22:3557–3564CrossRefGoogle Scholar
  14. 14.
    Bacci G, Ferrari S, Donati D et al (1998) Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep 5:1259–1263Google Scholar
  15. 15.
    Bacci G, Ferrari S, Mercuri M et al (2007) Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 78:377–384CrossRefGoogle Scholar
  16. 16.
    Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefGoogle Scholar
  17. 17.
    Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011CrossRefGoogle Scholar
  18. 18.
    Stark A, Kreicbergs A, Nilsonne ULF et al (1990) The age of osteosarcoma is increasing. JBJS (Br) 72-B:89–93Google Scholar
  19. 19.
    Ferrari S, Ruggieri P, Cefalo G et al (2012) Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 30:2112–2118CrossRefGoogle Scholar
  20. 20.
    Bielack SS, Smeland S, Whelan JS, EURAMOS-1 investigators et al (2015) Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 33:2279–2287CrossRefGoogle Scholar
  21. 21.
    Marina NM, Smeland S, Bielack SS et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17:1396–1408CrossRefGoogle Scholar
  22. 22.
    Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153:106–120Google Scholar
  23. 23.
    Huvos AG, Rosen G, Marcove RC (1977) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch PatholLab Med 101:14–18Google Scholar
  24. 24.
    Bielack SS, Wulff B, Delling G et al (1995) Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma Study Group (COSS). Med Pediatr Oncol 24:6–12CrossRefGoogle Scholar
  25. 25.
    Matsunobu A, Imai R, Kamada T et al (2012) Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer 118:4555–4563CrossRefGoogle Scholar
  26. 26.
    Brouwer CAJ, Gietema JA, van den Berg MP et al (2006) Long-term cardiac follow-up in survivors of a malignant bone tumor. Ann Oncol 17:1586–1591CrossRefGoogle Scholar
  27. 27.
    Kudawara I, Aoki Y, Ueda T et al (2013) Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother 25:41–48CrossRefGoogle Scholar

Copyright information

© SICOT aisbl 2019

Authors and Affiliations

  • Yoshinori Imura
    • 1
    Email author
  • Satoshi Takenaka
    • 2
  • Shigeki Kakunaga
    • 3
  • Takaaki Nakai
    • 4
  • Toru Wakamatsu
    • 1
  • Hidetatsu Outani
    • 2
  • Takaaki Tanaka
    • 1
  • Hironari Tamiya
    • 1
  • Kazuya Oshima
    • 5
  • Kenichiro Hamada
    • 2
  • Norifumi Naka
    • 1
  • Nobuhito Araki
    • 6
  • Ikuo Kudawara
    • 3
  • Takafumi Ueda
    • 3
  • Hideki Yoshikawa
    • 2
  1. 1.Musculoskeletal Oncology ServiceOsaka International Cancer InstituteOsakaJapan
  2. 2.Department of Orthopedic SurgeryOsaka University Graduate School of MedicineOsakaJapan
  3. 3.Department of Orthopedic SurgeryOsaka National HospitalOsakaJapan
  4. 4.Department of Orthopedic SurgeryKawachi General HospitalOsakaJapan
  5. 5.Department of Orthopedic SurgeryBell-land General HospitalSakaiJapan
  6. 6.Department of Orthopedic SurgeryAshiya Municipal HospitalAshiyaJapan

Personalised recommendations